James Howard
Neurology · Chapel Hill, NCNPI 1619082484
Payments from drug & device makers
Across 353 payments — averaging $4905.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$720K
- Argenx US, Inc.$499K
- UCB SA$391K
- UCB Biosciences Inc.$39K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- Regeneron$22K
- plus $35K from 11 others
Across 38 payments — averaging $954.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$11K
- UCB, Inc.$10K
- Regeneron$7K
- AstraZeneca$5K
- Merck Healthcare Kgaa$2K
- Novartis Pharma AG$2K
What the payments were for
- Consulting fees$211,56672%
- Speaking & faculty fees$29,54710%
- Travel & lodging$47,41216%
- Food & beverage$5,1142%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 101 | $719,640 |
| Argenx US, Inc. | 121 | $498,823 |
| UCB SA | 36 | $390,588 |
| UCB Biosciences Inc. | 6 | $39,321 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $26,500 |
| Regeneron | 34 | $21,626 |
| Amgen(2 entities) | 6 | $9,966 |
| F. Hoffmann-la Roche AG | 4 | $5,954 |
| UCB, Inc. | 20 | $5,379 |
| Merck Kgaa | 2 | $4,000 |
| Sanofi US Services Inc. | 2 | $3,545 |
| Vertex | 9 | $2,596 |
| H. Lundbeck A S | 1 | $2,100 |
| Biogen | 1 | $1,250 |
| Novartis | 1 | $131 |
| Sarepta Therapeutics, Inc. | 1 | $36 |
| Pfizer | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,731,477 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 16 | $3,907 |
| Pyridostigmine Bromide | 29 | $2,079 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chapel Hill
- Irena Dujmovic BasuroskiChapel Hill$1.2M
- Robert GreenwoodChapel Hill$906K
- Rebecca TraubChapel Hill$434K
- David HuangChapel Hill$400K
- Daniel RoqueChapel Hill$231K
- Mohammad BolouriCharlotte$16.6M
- Katherine PetersDurham$11M
- John ScagnelliRaleigh$9.3M
- T RaoCharlotte$4M
- Pramod SethiGreensboro$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.